New Palestine, IN, United States of America

Philip Arthur Hipskind

USPTO Granted Patents = 44 


 

Average Co-Inventor Count = 4.3

ph-index = 13

Forward Citations = 406(Granted Patents)


Location History:

  • New Palastine, IN (US) (2012 - 2015)
  • Indianapolis, IN (US) (2015 - 2016)
  • New Palestine, IN (US) (1996 - 2021)

Company Filing History:


Years Active: 1996-2021

Loading Chart...
Loading Chart...
Loading Chart...
44 patents (USPTO):

Title: The Inventor Profile: Philip Arthur Hipskind

Introduction

Philip Arthur Hipskind, a prolific inventor hailing from New Palestine, IN, has made significant contributions to the field of medicine with his groundbreaking patents.

Latest Patents

Hipskind's latest patents showcase his innovative spirit. The MET antibody drug conjugates he developed target and eliminate MET expressing tumor cells, offering a promising treatment for cancers. Additionally, his Notch pathway signaling inhibitor compounds have shown potential in treating various cancers and sensorineural hearing loss.

Career Highlights

With an impressive 44 patents to his name, Philip Arthur Hipskind has left a lasting impact on the pharmaceutical industry. Throughout his career, he has worked with reputable companies such as Eli Lilly and Company and Deciphera Pharmaceuticals, LLC, further solidifying his expertise in the field.

Collaborations

Hipskind has had the privilege of collaborating with esteemed professionals in the industry, including Karen Lynn Lobb and James Arthur Nixon. These collaborations have not only enriched his work but have also paved the way for innovative solutions in cancer treatment and hearing loss therapies.

Conclusion

In conclusion, Philip Arthur Hipskind's inventive mind and dedication to advancing medical science have positioned him as a pioneer in the field of pharmaceuticals. His patents continue to inspire new developments and offer hope for improved treatments in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…